FDA — authorised 28 August 2020
- Marketing authorisation holder: NOVO NORDISK INC
- Status: approved
🇺🇸 Sogroya in United States
FDA authorised Sogroya on 28 August 2020
Marketing authorisations
FDA — authorised 28 August 2020
- Application: BLA761156
- Marketing authorisation holder: NOVO NORDISK INC
- Local brand name: SOGROYA
- Indication: SOLUTION — SUBCUTANEOUS
- Status: approved
Sogroya in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Metabolic approved in United States
Frequently asked questions
Is Sogroya approved in United States?
Yes. FDA authorised it on 28 August 2020; FDA authorised it on 28 August 2020.
Who is the marketing authorisation holder for Sogroya in United States?
NOVO NORDISK INC holds the US marketing authorisation.